{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:50:57Z","timestamp":1791834657483,"version":"4.3.4"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK056341"],"award-info":[{"award-number":["P30 DK056341"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["24CDA1269277"],"award-info":[{"award-number":["24CDA1269277"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tem.2026.09.015","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:13:00Z","timestamp":1791778380000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unraveling the mechanistic mystery of SGLT2 inhibitors in heart failure"],"prefix":"10.1016","author":[{"given":"Tan","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5411-3674","authenticated-orcid":false,"given":"Brian N.","family":"Finck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1454-0097","authenticated-orcid":false,"given":"Justin H.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2026.09.015_bb0005","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tem.2026.09.015_bb0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.tem.2026.09.015_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2026.179176","article-title":"Canagliflozin improves early-stage cardiac hypertrophy and energy metabolism in TAC mice","volume":"1031","author":"Luo","year":"2026","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tem.2026.09.015_bb0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCRESAHA.124.324823","article-title":"SGLT2 inhibitors act independently of SGLT2 to confer benefit for HFrEF in mice","volume":"135","author":"Berger","year":"2024","journal-title":"Circ. Res."},{"key":"10.1016\/j.tem.2026.09.015_bb0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.tem.2026.09.015_bb0030","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tem.2026.09.015_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.yjmcc.2013.02.006","article-title":"NHE-1: still a viable therapeutic target","volume":"61","author":"Karmazyn","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.tem.2026.09.015_bb0040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.tem.2026.09.015_bb0045","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tem.2026.09.015_bb0050","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.tem.2026.09.015_bb0055","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","article-title":"Cardiac late sodium channel current is a molecular target for the sodium\/glucose cotransporter 2 inhibitor empagliflozin","volume":"143","author":"Philippaert","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.tem.2026.09.015_bb0060","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cvr\/cvae095","article-title":"Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF","volume":"120","author":"Trum","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.tem.2026.09.015_bb0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1126\/science.aeh4856","article-title":"SGLT2 inhibitors activate pantothenate kinase in the human heart","volume":"393","author":"Forelli","year":"2026","journal-title":"Science"},{"key":"10.1016\/j.tem.2026.09.015_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2026.156568","article-title":"The early metabolic cardiac targets of empagliflozin during the development of heart failure, independent of SGLT2 inhibition","volume":"178","author":"Chen","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.tem.2026.09.015_bb0075","doi-asserted-by":"crossref","DOI":"10.1172\/JCI192333","article-title":"SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2","volume":"136","author":"Abdualkader","year":"2026","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tem.2026.09.015_bb0080","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176708","article-title":"SGLT2 inhibition alters substrate utilization and mitochondrial redox in the normal and failing heart","volume":"134","author":"Goedeke","year":"2024","journal-title":"J. Clin. Invest."}],"container-title":["Trends in Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276026002675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276026002675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:40:40Z","timestamp":1791834040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276026002675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":16,"alternative-id":["S1043276026002675"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2026.09.015","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the mechanistic mystery of SGLT2 inhibitors in heart failure","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2026.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}